Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Rating Lowered to “Hold” at Zacks Research

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

Separately, Wall Street Zen upgraded Bayer Aktiengesellschaft from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Two analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Stock Up 0.7%

OTCMKTS BAYRY opened at $7.61 on Monday. The company has a current ratio of 1.13, a quick ratio of 0.73 and a debt-to-equity ratio of 1.04. Bayer Aktiengesellschaft has a 12 month low of $4.79 and a 12 month high of $8.70. The stock’s 50 day moving average is $8.06 and its 200 day moving average is $7.67. The stock has a market cap of $29.90 billion, a PE ratio of -7.85, a P/E/G ratio of 3.62 and a beta of 0.90.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its earnings results on Wednesday, August 6th. The company reported $0.35 EPS for the quarter, topping the consensus estimate of $0.25 by $0.10. The firm had revenue of $12.42 billion for the quarter, compared to the consensus estimate of $10.79 billion. Bayer Aktiengesellschaft had a negative net margin of 7.61% and a positive return on equity of 15.44%. Research analysts predict that Bayer Aktiengesellschaft will post 1.31 EPS for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.